STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
Leonard Buckbinder(Pfizer (United States)), Darrin D. Stuart(Proteostasis Therapeutics (United States))
Cited by 67
Related Papers
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure
|Nature Communications|2020|924
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma
|ACS Medicinal Chemistry Letters|2015|54
CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations
|Cancer Research|2006|25
Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors
|ACS Medicinal Chemistry Letters|2014|13